ZIOPHARM Oncology (ZIOP) Posts Q3 Loss of $0.13, Better Y/Y
More News related to ZIOP
- Dr. Lewis to Participate in the Inaugural University College London UCL Finance Conference
- Dr. Lewis to Serve on Sarcoma Panel
- Rodman & Renshaw Starts Ziopharm Oncology (ZIOP) at Market Outperform
- Dr. Lewis to Participate as Chairman and Invited Lecturer at the 2nd Annual International Conference on Drug Discovery & Therapy, Dubai, UAE
- ZIOPHARM Receives Important Palifosfamide U.S. Patent Allowance
More News related to Earnings
- MEDTOX Scientific Inc. (MTOX) Posts Q4 Loss of $0.02, Misses Views
- NeuroMetrix Inc. (NURO) Posts Q4 Loss of $0.08, Narrower Y/Y
- IntercontinentalExchange (ICE) Posts Q4 EPS of $1.13, Misses by 1c; Increases Stock Buyback to $300M
- Elan Corp. (ELN) Posts Q4 Loss of $0.10, Beats by 8c
- Omnicom Group (OMC) Posts Q4 EPS of $0.73, Beats by 1c
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) reports Q3 loss of $0.13, compared to ($0.26) in the same quarter last year.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
